CoChat
Sign Up
Cited by 115

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies

Walsh, Roddy, Offerhaus, Joost A., Tadros, Rafik, Bezzina, Connie R.·2022·Nature Reviews Cardiology
DOI 10.1038/s41569-021-00608-2
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41569-021-00608-2

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 85

  1. Seidman, C. E. & Seidman, J. G. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ. Res. 108, 743–750 (2011). · DOI · Paper page
  2. Walsh, R. et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet. Med. 19, 192–203 (2017). · DOI
  3. Ho, C. Y. et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation 138, 1387–1398 (2018). · DOI · Paper page
  4. Mazzarotto, F. et al. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. Circulation 141, 387–398 (2020). · DOI
  5. Ingles, J. et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ. Genom. Precis. Med. 12, e002460 (2019). · DOI
  6. Jordan, E. et al. An evidence-based assessment of genes in dilated cardiomyopathy. Circulation https://doi.org/10.1161/CIRCULATIONAHA.120.053033 (2021). · DOI
  7. Tadros, R. et al. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat. Genet. 53, 128–134 (2021). · DOI
  8. Harper, A. R. et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat. Genet. 53, 135–142 (2021). · DOI · Paper page
  9. Ziane, R. et al. Cell membrane expression of cardiac sodium channel Na(v)1.5 is modulated by alpha-actinin-2 interaction. Biochemistry 49, 166–178 (2010). · DOI
  10. Lu, L. et al. Molecular coupling of a Ca2+-activated K+ channel to L-type Ca2+ channels via alpha-actinin2. Circ. Res. 100, 112–120 (2007). · DOI
  11. Chiu, C. et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 55, 1127–1135 (2010). · DOI
  12. Girolami, F. et al. Novel α-actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. Circ. Cardiovasc. Genet. 7, 741–750 (2014). · DOI
  13. Bagnall, R. D., Molloy, L. K., Kalman, J. M. & Semsarian, C. Exome sequencing identifies a mutation in the ACTN2 gene in a family with idiopathic ventricular fibrillation, left ventricular noncompaction, and sudden death. BMC Med. Genet. 15, 99 (2014). · DOI
  14. Prondzynski, M. et al. Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy. EMBO Mol. Med. 11, e11115 (2019). · DOI
  15. Mazzarotto, F. et al. Systematic large-scale assessment of the genetic architecture of left ventricular noncompaction reveals diverse etiologies. Genet. Med. 23, 856–864 (2021). · DOI
  16. Singer, E. S. et al. Characterization of clinically relevant copy-number variants from exomes of patients with inherited heart disease and unexplained sudden cardiac death. Genet. Med. 23, 86–93 (2021). · DOI
  17. Lindholm, M. E. et al. Mono- and bi-allelic protein truncating variants in alpha-actinin 2 cause cardiomyopathy through distinct mechanisms. bioRxiv https://doi.org/10.1101/2020.11.19.389064 (2020). · DOI
  18. Arvanitis, M. et al. Genome-wide association and multi-omic analyses reveal ACTN2 as a gene linked to heart failure. Nat. Commun. 11, 1122 (2020). · DOI
  19. Almomani, R. et al. Biallelic truncating mutations in ALPK3 cause severe pediatric cardiomyopathy. J. Am. Coll. Cardiol. 67, 515–525 (2016). · DOI
  20. Phelan, D. G. et al. ALPK3-deficient cardiomyocytes generated from patient-derived induced pluripotent stem cells and mutant human embryonic stem cells display abnormal calcium handling and establish that ALPK3 deficiency underlies familial cardiomyopathy. Eur. Heart J. 37, 2586–2590 (2016). · DOI
  21. Çağlayan, A. O. et al. ALPK3 gene mutation in a patient with congenital cardiomyopathy and dysmorphic features. Cold Spring Harb. Mol. Case Stud. 3, a001859 (2017). · DOI
  22. Jaouadi, H. et al. Novel ALPK3 mutation in a Tunisian patient with pediatric cardiomyopathy and facio-thoraco-skeletal features. J. Hum. Genet. 63, 1077–1082 (2018). · DOI
  23. Al Senaidi, K. et al. Phenotypic spectrum of ALPK3-related cardiomyopathy. Am. J. Med. Genet. A 179, 1235–1240 (2019). · DOI
  24. Jorholt, J. et al. Two new cases of hypertrophic cardiomyopathy and skeletal muscle features associated with ALPK3 homozygous and compound heterozygous variants. Genes 11, 1201 (2020). · DOI
  25. Herkert, J. C. et al. Expanding the clinical and genetic spectrum of ALPK3 variants: phenotypes identified in pediatric cardiomyopathy patients and adults with heterozygous variants. Am. Heart J. 225, 108–119 (2020). · DOI
  26. Lopes, L. R. et al. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehab424 (2021). · DOI
  27. Cheawsamoot, C. et al. A pathogenic variant in ALPK3 is associated with an autosomal dominant adult-onset hypertrophic cardiomyopathy. Circ. Genom. Precis. Med. 13, e003127 (2020). · DOI
  28. Vafiadaki, E., Arvanitis, D. A. & Sanoudou, D. Muscle LIM protein: master regulator of cardiac and skeletal muscle functions. Gene 566, 1–7 (2015). · DOI
  29. Walsh, R. et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur. Heart J. 38, 3461–3468 (2017).
  30. Geier, C. et al. Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Hum. Mol. Genet. 17, 2753–2765 (2008). · DOI
  31. Salazar-Mendiguchía, J. et al. The p.(Cys150Tyr) variant in CSRP3 is associated with late-onset hypertrophic cardiomyopathy in heterozygous individuals. Eur. J. Med. Genet. 63, 104079 (2020). · DOI
  32. Janin, A., Bessière, F., Chauveau, S., Chevalier, P. & Millat, G. First identification of homozygous truncating CSRP3 variants in two unrelated cases with hypertrophic cardiomyopathy. Gene 676, 110–116 (2018). · DOI
  33. Lipari, M. et al. Identification of a variant hotspot in MYBPC3 and of a novel CSRP3 autosomal recessive alteration in a cohort of Polish patients with hypertrophic cardiomyopathy. Pol. Arch. Intern. Med. 130, 89–99 (2020). · DOI
  34. Arber, S. et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88, 393–403 (1997). · DOI
  35. Knöll, R. et al. A common MLP (muscle LIM protein) variant is associated with cardiomyopathy. Circ. Res. 106, 695–704 (2010). · DOI
  36. Taniguchi, K. et al. Mammalian formin Fhod3 regulates actin assembly and sarcomere organization in striated muscles. J. Biol. Chem. 284, 29873–29881 (2009). · DOI
  37. Wooten, E. C. et al. Formin homology 2 domain containing 3 variants associated with hypertrophic cardiomyopathy. Circ. Cardiovasc. Genet. 6, 10–18 (2013). · DOI
  38. Esslinger, U. et al. Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy. PLoS One 12, e0172995 (2017). · DOI
  39. Ochoa, J. P. et al. Formin homology 2 domain containing 3 (FHOD3) is a genetic basis for hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 72, 2457–2467 (2018). · DOI
  40. Ochoa, J. P. et al. Deletions of specific exons of FHOD3 detected by next-generation sequencing are associated with hypertrophic cardiomyopathy. Clin. Genet. 98, 86–90 (2020). · DOI
  41. Semsarian, C., Ingles, J. & Bagnall, R. D. Revisiting genome sequencing data in light of novel disease gene associations. J. Am. Coll. Cardiol. 73, 1365–1366 (2019). · DOI
  42. Lesurf, R. et al. Whole genome sequencing delineates regulatory and novel genic variants in childhood cardiomyopathy. medRxiv https://doi.org/10.1101/2020.10.12.20211474 (2020). · DOI
  43. Wu, G. et al. Variant spectrum of formin homology 2 domain-containing 3 gene in Chinese patients with hypertrophic cardiomyopathy. J. Am. Heart Assoc. 10, e018236 (2021).
  44. Matsuyama, S. et al. Interaction between cardiac myosin-binding protein C and formin Fhod3. Proc. Natl Acad. Sci. USA 115, E4386–E4395 (2018). · DOI
  45. Arimura, T. et al. Dilated cardiomyopathy-associated FHOD3 variant impairs the ability to induce activation of transcription factor serum response factor. Circ. J. 77, 2990–2996 (2013). · DOI
  46. Kan-O, M. et al. Mammalian formin Fhod3 plays an essential role in cardiogenesis by organizing myofibrillogenesis. Biol. Open 1, 889–896 (2012). · DOI
  47. Vorgerd, M. et al. A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. Am. J. Hum. Genet. 77, 297–304 (2005). · DOI
  48. Valdés-Mas, R. et al. Mutations in filamin C cause a new form of familial hypertrophic cardiomyopathy. Nat. Commun. 5, 5326 (2014). · DOI
  49. Verdonschot, J. A. J. et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum. Mutat. 41, 1091–1111 (2020). · DOI
  50. Gómez, J. et al. Screening of the Filamin C gene in a large cohort of hypertrophic cardiomyopathy patients. Circ. Cardiovasc. Genet. 10, e001584 (2017). · DOI
  51. Cui, H. et al. Mutation profile of FLNC gene and its prognostic relevance in patients with hypertrophic cardiomyopathy. Mol. Genet. Genomic Med. 6, 1104–1113 (2018). · DOI
  52. Thomson, K. L. et al. Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield. Genet. Med. 21, 1576–1584 (2019). · DOI
  53. Ortiz-Genga, M. F. et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J. Am. Coll. Cardiol. 68, 2440–2451 (2016). · DOI
  54. Begay, R. L. et al. Filamin C truncation mutations are associated with arrhythmogenic dilated cardiomyopathy and changes in the cell-cell adhesion structures. JACC Clin. Electrophysiol. 4, 504–514 (2018). · DOI
  55. Ader, F. et al. FLNC pathogenic variants in patients with cardiomyopathies: prevalence and genotype-phenotype correlations. Clin. Genet. 96, 317–329 (2019). · DOI
  56. Janin, A. et al. Truncating mutations on myofibrillar myopathies causing genes as prevalent molecular explanations on patients with dilated cardiomyopathy. Clin. Genet. 92, 616–623 (2017). · DOI
  57. Hall, C. L. et al. Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype. Int. J. Cardiol. 307, 101–108 (2020). · DOI
  58. Goli, R. et al. Genetic and phenotypic landscape of peripartum cardiomyopathy. Circulation 143, 1852–1862 (2021). · DOI
  59. Dalkilic, I., Schienda, J., Thompson, T. G. & Kunkel, L. M. Loss of FilaminC (FLNc) results in severe defects in myogenesis and myotube structure. Mol. Cell. Biol. 26, 6522–6534 (2006). · DOI
  60. van der Zwaag, P. A. et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199–1207 (2012). · DOI
  61. Schmitt, J. P. et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, 1410–1413 (2003). · DOI
  62. Haghighi, K. et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111, 869–876 (2003). · DOI · Paper page
  63. Li, Z. et al. A PLN nonsense variant causes severe dilated cardiomyopathy in a novel autosomal recessive inheritance mode. Int. J. Cardiol. 279, 122–125 (2019). · DOI
  64. Mademont-Soler, I. et al. Additional value of screening for minor genes and copy number variants in hypertrophic cardiomyopathy. PLoS One 12, e0181465 (2017). · DOI
  65. Vanninen, S. U. M. et al. Heterozygous junctophilin-2 (JPH2) p.(Thr161Lys) is a monogenic cause for HCM with heart failure. PLoS One 13, e0203422 (2018).
  66. Sabater-Molina, M. et al. Mutation in JPH2 cause dilated cardiomyopathy. Clin. Genet. 90, 468–469 (2016). · DOI
  67. Vasilescu, C. et al. Genetic basis of severe childhood-onset cardiomyopathies. J. Am. Coll. Cardiol. 72, 2324–2338 (2018). · DOI
  68. Jones, E. G. et al. Analysis of enriched rare variants in JPH2-encoded junctophilin-2 among greater middle eastern individuals reveals a novel homozygous variant associated with neonatal dilated cardiomyopathy. Sci. Rep. 9, 9038 (2019).
  69. Takeshima, H., Komazaki, S., Nishi, M., Iino, M. & Kangawa, K. Junctophilins: a novel family of junctional membrane complex proteins. Mol. Cell 6, 11–22 (2000).
  70. Salazar-Mendiguchía, J. et al. Mutations in TRIM63 cause an autosomal-recessive form of hypertrophic cardiomyopathy. Heart 106, 1342–1348 (2020). · DOI
  71. Su, M. et al. Rare variants in genes encoding MuRF1 and MuRF2 are modifiers of hypertrophic cardiomyopathy. Int. J. Mol. Sci. 15, 9302–9313 (2014). · DOI
  72. Witt, C. C. et al. Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2. EMBO J. 27, 350–360 (2008). · DOI
  73. Willis, M. S. et al. Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ. Res. 100, 456–459 (2007). · DOI
  74. Hedberg-Oldfors, C. et al. Cardiomyopathy with lethal arrhythmias associated with inactivation of KLHL24. Hum. Mol. Genet. 28, 1919–1929 (2019). · DOI
  75. Lin, Z. et al. Stabilizing mutations of KLHL24 ubiquitin ligase cause loss of keratin 14 and human skin fragility. Nat. Genet. 48, 1508–1516 (2016). · DOI
  76. Schwieger-Briel, A. et al. Epidermolysis bullosa simplex with KLHL24 mutations is associated with dilated cardiomyopathy. J. Invest. Dermatol. 139, 244–249 (2019). · DOI
  77. Vermeer, M. C. S. C. et al. Gain-of-function mutation in ubiquitin-ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues. J. Clin. Invest. https://doi.org/10.1172/JCI140615 (2021). · DOI
  78. Domínguez, F. et al. Dilated cardiomyopathy due to BLC2-associated athanogene 3 (BAG3) mutations. J. Am. Coll. Cardiol. 72, 2471–2481 (2018). · DOI
  79. Alfares, A. A. et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet. Med. 17, 880–888 (2015). · DOI · Paper page
  80. Kelly, M. A. et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s inherited cardiomyopathy expert panel. Genet. Med. 20, 351–359 (2018). · DOI
  81. Walsh, R. et al. Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. Genome Med. 11, 5 (2019). · DOI
  82. Olivotto, I. et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 62, 449–457 (2013). · DOI
  83. Castel, S. E. et al. Modified penetrance of coding variants by cis-regulatory variation contributes to disease risk. Nat. Genet. 50, 1327–1334 (2018). · DOI · Paper page
  84. Neubauer, S. et al. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry. J. Am. Coll. Cardiol. 74, 2333–2345 (2019). · DOI
  85. Montefiori, L. E. et al. A promoter interaction map for cardiovascular disease genetics. eLife 7, e35788 (2018). · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Walsh, R., Offerhaus, J. A., Tadros, R., & Bezzina, C. R.
Venue
Nature Reviews Cardiology
Publisher
Springer Science and Business Media LLC
Published
2021-09-15
Volume
19
Issue
3
Pages
151-167
ISSN
  • 1759-5002
  • 1759-5010
DOI
10.1038/s41569-021-00608-2
Cited by
115
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review